Overview

Detailed Summary

Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets.
Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter.
Management is executing a clear capacity roadmap: Nandesari greenfield (51,200 MT, ~Rs.150 crore) commissioning by Q4 FY26 and Dahej battery materials Phase‑1 (25,000 MT, ~Rs.300 crore) targeted for early CY27, indicating a strategic pivot into high‑growth battery materials while expanding core pharma and specialty capacities.
Sudeep’s battery strategy positions it as an early large non‑Chinese LFP supplier: the company reports 34 battery value‑chain customers, 26 approvals, multiple MoUs and commercial orders from upgraded capacity, leveraging a proprietary ‘green chemistry’ claim and port proximity to serve global OEMs and CAM producers.
Product and regulatory moats are meaningful: 6 proprietary technologies, 420 R&D projects, multiple global certifications (FDA, EDQM, EXCiPACT) and long customer relationships (average >7 years for top customers) underpin pricing power, repeat business (84% repeat revenue) and faster entry into regulated markets such as Europe and North America.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 8,235 Cr
Volatility: Low Risk
P/E Ratio: 47.6
Industry P/E: 34.1
PEG Ratio: 1.8
P/B Ratio: 9.3
52W High: 815.85
52W Low: 524.95

Sales CAGR

1Y: 9.30%
3Y: 1.13%
5Y: 23.73%
10Y: —

Profit CAGR

1Y: 4.14%
3Y: 22.33%
5Y: 39.63%
10Y: —

ROE

TTM: 19.57%
3Y: 26.06%
5Y: 27.09%
10Y: —

ROCE

TTM: 22.16%
3Y: 33.97%
5Y: 34.49%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AKUMS		608.65	9,580 Cr	37.54	2.89	0.48	7.70	10.95	4.71
STAR		990.20	9,119 Cr	16.40	2.93	0.51	17.90	17.30	8.29
BLUEJET		499.30	8,646 Cr	34.89	6.36	0.24	18.22	24.16	15.10
SUDEEPPHRM		725.40	8,235 Cr	47.63	9.32	0.21	19.57	22.16	14.83
SANOFI		3142.00	8,112 Cr	19.63	9.43	3.49	42.11	52.41	25.64
SUPRIYA		936.15	7,534 Cr	36.03	6.29	0.11	17.46	23.00	15.41
JSLL		594.30	7,372 Cr	33.24	15.78	0.76	47.50	52.11	32.88
Median: 7 Co.	—	725.40	8,235 Cr	34.89	6.36	0.48	18.22	23.00	15.10

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	149	116	158	125	163	172	182
Expenses	85	76	99	81	107	112	120
Operating Profit	63	39	59	44	55	60	63
OPM %	42.65	34.01	37.31	35.12	34.09	34.80	34.33
Other Income	1.87	2.44	3.76	5.16	10	6.84	6.42
Interest	1.05	1.41	1.85	1.71	2.28	1.17	2.44
Depreciation	2.58	2.67	2.83	3.25	3.81	3.86	3.88
Profit Before Tax	62	38	58	44	60	62	63
Tax %	21.01	23.74	23.63	29.04	21.43	22.79	22.57
Net Profit	49	29	44	31	47	48	49
EPS in Rs	—	—	—	2.41	—	4.29	4.38

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2024	Mar 2025
Sales	123	215	343	459	502
Expenses	98	171	276	278	312
Operating Profit	25	44	67	182	190
OPM %	20.64	20.49	19.67	39.55	37.84
Other Income	3.22	3.44	7.39	6.10	9.33
Interest	0.93	0.97	1.72	3.92	5.85
Depreciation	3.07	3.53	4.53	9.01	11
Profit Before Tax	25	43	69	175	183
Tax %	26.68	22.50	26.87	23.80	24.13
Net Profit	18	33	50	133	139
EPS in Rs	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2024	Mar 2025
Equity Capital	1.41	1.41	1.41	1.41	9.72
Reserves	80	113	162	355	481
Borrowings	17	31	84	78	140
Other Liabilities	33	67	97	80	87
Total Liabilities	131	213	344	514	717
Fixed Assets	60	68	137	180	189
CWIP	8.16	24	8.13	45	88
Investments	6.00	19	0.00	0.13	0.14
Other Assets	57	102	199	289	439
Total Assets	131	213	344	514	717

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2024	Mar 2025
Cash from Operating Activity	9.87	35	-2.98	66	49
Cash from Investing Activity	-22	-40	-38	-49	-79
Cash from Financing Activity	12	13	51	-13	53
Net Cash Flow	-0.16	7.86	9.52	3.67	23

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2025	Nov 2025	Dec 2025	Mar 2026
Promoters	100.00%	76.15%	76.15%	76.15%
FIIs	0.00%	1.54%	1.67%	1.55%
DIIs	0.00%	14.76%	17.60%	18.11%
Public	0.00%	7.54%	4.58%	4.18%
Total Shareholders	16	2,17,982	43,599	36,503

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Sudeep Pharma Ltd

Sudeep Pharma Ltd (SUDEEPPHRM) is currently trading at 752.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets. Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter. Management is executing a clear capacity roadmap: Nandesari greenfield (51,200 MT, ~Rs.150 crore) commissioning by Q4 FY26 and Dahej battery materials Phase‑1 (25,000 MT, ~Rs.300 crore) targeted for early CY27, indicating a strategic pivot into high‑growth battery materials while expanding core pharma and specialty capacities. Sudeep’s battery strategy positions it as an early large non‑Chinese LFP supplier: the company reports 34 battery value‑chain customers, 26 approvals, multiple MoUs and commercial orders from upgraded capacity, leveraging a proprietary ‘green chemistry’ claim and port proximity to serve global OEMs and CAM producers. Product and regulatory moats are meaningful: 6 proprietary technologies, 420 R&D projects, multiple global certifications (FDA, EDQM, EXCiPACT) and long customer relationships (average >7 years for top customers) underpin pricing power, repeat business (84% repeat revenue) and faster entry into regulated markets such as Europe and North America.

Over the past 52 weeks, Sudeep Pharma Ltd has traded between a low of ₹524.95 and a high of ₹815.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sudeep Pharma Ltd has a market capitalization of approximately 8,235.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sudeep Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 47.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8,235.08 Cr, Sudeep Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sudeep Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 47.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Sudeep Pharma Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison